Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1

Publication
Article
Supplements and Featured PublicationsTherapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Volume 1
Issue 1

This publication includes a summary of data on recent therapeutic advances in treating metastatic HER2-positive breast cancer that was presented during a series of 4 live regional broadcasts across the United States (California, Illinois, Texas, and Washington). Medical oncologists specializing in the treatment of breast cancer across those regions provide key insights on factors that influence planning and treatment selection.

Download Issue PDF
Articles in this issue
breast cancer
Therapeutic Considerations in Metastatic HER2+ Breast Cancer: Part 1
Related Videos
Elias Jabbour, MD
A panel of 4 experts on colorectal cancer
Erin Frances Cobain, MD
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Related Content
Breast Cancer - stock.adobe.com

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

May 9th 2024
Article
D. Ross Camidge, MD, PhD; B.J. Rimel, MD, assistant professor, obstetrics and gynecology, Cedars-Sinai, medical director, Cancer Clinical Trials Office, Cedars-Sinai Cancer Institute, health sciences associate clinical professor, Department of Obstetrics and Gynecology, University of California, Los Angeles

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

April 15th 2024
Podcast
Nathalie LeVasseur, MD, FRCPC

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024
Article
Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024
Podcast
Erin Frances Cobain, MD, of the University of Michigan Rogel Cancer Center

Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management

May 2nd 2024
Article
Antonio Llombart-Cussac, MD, PhD

Trastuzumab Plus Pertuzumab Provides Sustained iDFS Benefit in HER2+ Breast Cancer

May 1st 2024
Article